

UNIVERSITÀ DEGLI STUDI DI MILANO

Procedura di selezione per la chiamata a professore di II fascia da ricoprire ai sensi dell'art. 18, comma 1, della Legge n. 240/2010 per il settore concorsuale __06/B1_____,
(settore scientifico-disciplinare __Medicina Interna MED/09_____)
presso il Dipartimento di _Science Cliniche e di Comunità_____, Codice concorso __5012__

Marco Proietti

CURRICULUM VITAE

INFORMAZIONI PERSONALI (NON INSERIRE INDIRIZZO PRIVATO E TELEFONO FISSO O CELLULARE)

| | |
|-----------------|------------|
| COGNOME | PROIETTI |
| NOME | MARCO |
| DATA DI NASCITA | 08/06/1982 |

TITOLI

TITOLO DI STUDIO

(indicare la Laurea conseguita inserendo titolo, Ateneo, data di conseguimento, ecc.)

- Laurea in Medicina e Chirurgia presso "Sapienza-Università di Roma" in data 31/10/2008 con una tesi dal titolo: "ATTIVAZIONE PIASTRINICA NEL PAZIENTE AFFETTO DA SCOMPENSO CARDIACO: RUOLO DEL TUMOR NECROSIS FACTOR ALPHA" con votazione di 109/110.

TITOLO DI DOTTORE DI RICERCA O EQUIVALENTI, OVVERO, PER I SETTORI INTERESSATI, DEL DIPLOMA DI SPECIALIZZAZIONE MEDICA O EQUIVALENTE, CONSEGUITO IN ITALIA O ALL'ESTERO

(inserire titolo, ente, data di conseguimento, ecc.)

- Specializzazione in Medicina Interna presso "Sapienza-Università di Roma" in data 09/06/2015 con una tesi dal titolo: "INFLUENZA DELL'INDICE CAVIGLIA-BRACCIO SULL'INCIDENZA DI INFARTO DEL MIOCARDIO E MORTALITA' CARDIOVASCOLARE IN UNA CORTE DI PAZIENTI AFFETTI DI FIBRILLAZIONE ATRIALE NON VALVOLARE" con votazione di 70/70 e Lode.
- Dottorato di Ricerca in Tecnologie Biomediche in Medicina Clinica (31° ciclo) presso "Sapienza-Università di Roma" in data 26/02/2019 con una dissertazione finale dal titolo: "Atrial fibrillation as a clinical model of multimorbidity: current evidence, experimental data and a proposal for management".

ALTRI TITOLI CONSEGUITI

(inserire titolo, ente, data di conseguimento, ecc.)

- Corso di Alta Formazione in "Pianificazione e Analisi di Studi Clinici Osservazionali e Sperimentali" presso "Sapienza-Università di Roma", AA 2011/2012

ATTIVITÀ DIDATTICA

INSEGNAMENTI E MODULI

(inserire periodo [gg/mm/aa inizio e fine], anno accademico, corso laurea, numero di ore frontali, eventuale CFU)

- Incarico didattico di Geriatria (1° - 4° anno) presso SS in Geriatria, Università degli Studi di Milano / 16 ore di Lezioni Frontali - AA 2019/2020, AA 2020/2021, AA 2021/2022
- Incarico didattico SSD MED/09, Corso Integrato "Clinical Practice" (6° anno), Corso di Laurea International Medical School, Università degli Studi di Milano / 2 ore di Lezioni Frontali - AA 2019/2020; 5 ore di Lezioni Frontali - AA 2020/2021, AA 2021/2022
- Incarico didattico SSD MED/09, Corso Integrato "Clinica Medica 5° anno", Corso di Laurea Medicina e Chirurgia "Polo Centrale", Università degli Studi di Milano / 5 ore di Attività Professionalizzanti - AA 2019/2020; 6.5 ore di Attività Professionalizzanti - AA 2020/2021, AA 2021/2022
- Incarico didattico SSD MED/09, Corso Integrato "Scienze Mediche 1", Corso di Laurea Odontoiatria e Protesi Dentaria "Polo Centrale", Università degli Studi di Milano / 25 ore di Attività Professionalizzanti AA 2020/2021
- Incarico didattico SSD MED/09, Corso Integrato "Scienze Mediche 1", Corso di Laurea Odontoiatria e Protesi Dentaria "Polo San Paolo", Università degli Studi di Milano / 25 ore di Attività Professionalizzanti AA 2020/2021
- Incarico didattico SSD MED/09, Corso Integrato "Scienze Mediche", Corso di Laurea Assistenza Sanitaria, Università degli Studi di Milano / 15 ore di Lezioni Frontali - AA 2020/2021, AA 2021/2022
- Incarico didattico SSD MED/09, Corso Integrato "Salute dell'Adulto e dell'Anziano e Salute Neuropsichiatrica", Corso di Laurea Assistenza Sanitaria, Università degli Studi di Milano / 10 ore di Lezioni Frontali - AA 2020/2021, AA 2021/2022
- Incarico didattico SSD MED/09, Corso Integrato "Infermieristica in Area Critica", Corso di Laurea Infermieristica, Università degli Studi di Milano / 15 ore di Lezioni Frontali "Polo San Donato" - AA 2021/2022
- Incarico didattico SSD MED/09, Corso Integrato "Semeiotica e Patologia degli Apparati I", Corso di Laurea Medicina e Chirurgia "Polo San Donato", Università degli Studi di Milano / 8 ore di Lezioni Frontali - AA 2021/2022; 50 ore di Attività Professionalizzanti - AA 2021/2022
- Incarico didattico SSD MED/09, Corso Integrato "Semeiotica e Patologia degli Apparati II", Corso di Laurea Medicina e Chirurgia "Polo San Donato", Università degli Studi di Milano / 4 ore di Lezioni Frontali - AA 2021/2022; 50 ore di Attività Professionalizzanti - AA 2021/2022
- Incarico didattico SSD MED/09, Corso Integrato "Clinica Medica 6° anno", Corso di Laurea Medicina e Chirurgia "Polo San Donato", Università degli Studi di Milano / 10 ore di Lezioni Frontali - AA 2021/2022
- Incarico didattico SSD MED/09, Corso Integrato "Clinica Medica 6° anno", Corso di Laurea Medicina e Chirurgia "Polo San Giuseppe", Università degli Studi di Milano / 5 ore di Lezioni Frontali - AA 2021/2022
- Incarico didattico SSD MED/09, Corso Integrato "Urgenze ed Emergenze Medico-Chirurgiche", Corso di Laurea Medicina e Chirurgia "Polo San Donato", Università degli Studi di Milano / 4 ore di Lezioni Frontali - AA 2021/2022

ATTIVITÀ DI DIDATTICA INTEGRATIVA E DI SERVIZIO AGLI STUDENTI

ATTIVITÀ DI RELATORE DI ELABORATI DI LAUREA, DI TESI DI LAUREA MAGISTRALE, DI TESI DI DOTTORATO E DI TESI DI SPECIALIZZAZIONE

(inserire numero, anno accademico, ateneo, corso laurea, ecc.)

- Co-Relatore di 5 Tesi di Laurea in Medicina e Chirurgia, Università degli Studi di Milano / 2 Tesi AA 2018/2019; 1 Tesi AA 2020/2021; 2 Tesi AA 2021/2022
- Co-Relatore di 2 Tesi di Specializzazione in Medicina e Chirurgia, Università degli Studi di Milano / 2 Tesi - AA 2019/2020

ATTIVITÀ DI TUTORATO DEGLI STUDENTI DI CORSI DI LAUREA E DI LAUREA MAGISTRALE E DI TUTORATO DI DOTTORANDI DI RICERCA

(inserire anno accademico, corso laurea, ecc.)

- Tutoraggio Specializzandi della SS in Geriatria, Università degli Studi di Milano - AA 2019/2020, AA 2020/2021, AA 2021/2022
- Tutor di 2 Studenti, Corso di Laurea in Medicina e Chirurgia "Polo San Donato", Università degli Studi di Milano - AA 2021/2022

ATTIVITÀ DI RICERCA SCIENTIFICA

PUBBLICAZIONI SCIENTIFICHE

(per ciascuna pubblicazione indicare: nomi degli autori, titolo completo, casa editrice, data e luogo di pubblicazione, codice ISBN, ISSN, DOI o altro equivalente)

1. Romiti GF, **Proietti M**, Vitolo M, Bonini N, Fawzy AM, Ding WY, Fauchier L, Marin F, Nabauer M, Dan GA, Potpara TS, Boriani G, Lip GYH; ESC-EHRA EORP-AF General Long-Term Registry Investigators. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry. BMC Med. 2022 Sep 2;20(1):326. doi: 10.1186/s12916-022-02526-7.
2. **Proietti M**, Romiti GF, Vitolo M, Borgi M, Rocco AD, Farcomeni A, Miyazawa K, Healey JS, Lane DA, Boriani G, Basili S, Lip GYH. Epidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: A systematic review and meta-regression. Eur J Intern Med. 2022 Sep;103:84-94. doi: 10.1016/j.ejim.2022.06.023.
3. **Proietti M**, Romiti GF, Basili S. The case of diabetes mellitus and atrial fibrillation: Underlining the importance of non-cardiovascular comorbidities. Eur J Intern Med. 2022 Sep;103:38-40. doi: 10.1016/j.ejim.2022.06.017.
4. Romiti GF, **Proietti M**, Bonini N, Ding WY, Boriani G, Huisman MV, Lip GYH; GLORIA-AF Investigators. Clinical Complexity Domains, Anticoagulation, and Outcomes in Patients with Atrial Fibrillation: A Report from the GLORIA-AF Registry Phase II and III. Thromb Haemost. 2022 Aug 29. doi: 10.1055/s-0042-1756355. Epub ahead of print.
5. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, Sanchez PL, Marin Ortuño F, Vazquez Rodriguez JM, Domingo-Fernández A, Lozano I, Roncaglioni MC, Baviera M, Foresta A, Ojeda-Fernandez L, Colivicchi F, Di Fusco SA, Doehner W, Meyer A, Schiele F, Ecarnot F, Linhart A, Lubanda JC, Barczy G, Merkely B, Ponikowski P, Kasprzak M, Fernandez Alvira JM, Andres V, Bueno H, Collier T, Van de Werf F, Perel P, Rodriguez-Manero M, Alonso Garcia A, **Proietti M**, Schoos MM, Simon T, Fernandez Ferro J, Lopez N, Beghi E, Bejot Y, Vivas D, Cordero A, Ibañez B, Fuster V; SECURE Investigators. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022 Aug 26. doi: 10.1056/NEJMoa2208275. Epub ahead of print.
6. Vitolo M, **Proietti M**, Malavasi VL, Bonini N, Romiti GF, Imberti JF, Fauchier L, Marin F, Nabauer M, Potpara TS, Dan GA, Kalarus Z, Maggioni AP, Lane DA, Lip GYH, Boriani G; ESC-EHRA EORP-AF Long-Term General Registry Investigators. Adherence to the "Atrial fibrillation Better Care" (ABC) pathway in patients with atrial fibrillation and cancer: A report from the ESC-EHRA EURObservational Research Programme in atrial fibrillation (EORP-AF) General Long-Term Registry. Eur J Intern Med. 2022 Aug 23:S0953-6205(22)00276-X. doi: 10.1016/j.ejim.2022.08.004. Epub ahead of print.
7. Maira D, Duca L, Busti F, Consonni D, Salvatici M, Vianello A, Milani A, Guzzardella A, Di Pierro E, Aliberti S, Baldini IM, Bandera A, Blasi F, Cassinerio E, Cesari M, Fracanzani AL, Grasselli G, Graziadei G, Lombardi R, Marchi G, Montano N, Monzani V, Peyvandi F, **Proietti M**, Sandri M, Valenti L, Cappellini MD, Girelli D, Protti A, Motta I. The role of hypoxia and inflammation in the regulation of iron metabolism and erythropoiesis in COVID-19: The IRONCOVID study. Am J Hematol. 2022 Aug 15. doi: 10.1002/ajh.26679. Epub ahead of print.
8. Johnsen SP, **Proietti M**, Maggioni AP, Lip GYH. A multinational European network to implement integrated care in elderly multimorbid atrial fibrillation patients: the AFFIRMO Consortium. Eur Heart J. 2022 Aug 14;43(31):2916-2918. doi: 10.1093/eurheartj/ehac265.
9. Raparelli V, Santilli F, Marra AM, Romiti GF, Succurro E, Licata A, Buzzetti E, Piano S, Masala M, Suppressa P, Becattini C, Muiesan ML, Russo G, Cogliati C, **Proietti M**, Basili S; Italian Society of Internal Medicine (SIMI). The SIMI Gender '5 Ws' Rule for the integration of sex and gender-related variables in clinical studies towards internal medicine equitable research. Intern Emerg Med. 2022 Aug 6. doi: 10.1007/s11739-022-03049-y. Epub ahead of print.

10. **Proietti M**, Romiti GF, Vitolo M, Harrison SL, Lane DA, Fauchier L, Marin F, Năbauer M, Potpara TS, Dan GA, Maggioni AP, Cesari M, Boriani G, Lip GYH; ESC-EHRA EORP-AF General Long-Term Registry Investigators. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe. *Age Ageing*. 2022 Aug 2;51(8):afac192. doi: 10.1093/ageing/afac192.
11. **Proietti M**, Romiti GF, Raparelli V, Diemberger I, Boriani G, Dalla Vecchia LA, Bellelli G, Marzetti E, Lip GY, Cesari M. Frailty prevalence and impact on outcomes in patients with atrial fibrillation: A systematic review and meta-analysis of 1,187,000 patients. *Ageing Res Rev*. 2022 Aug;79:101652. doi: 10.1016/j.arr.2022.101652.
12. Biskup E, Marra AM, Ambrosino I, Barbagelata E, Basili S, de Graaf J, Gonzalvez-Gasch A, Kaaja R, Karlafti E, Lotan D, Kautzky-Willer A, Perticone M, Politi C, Schenck-Gustafsson K, Vilas-Boas A, Roeters van Lennep J, Gans EA, Regitz-Zagrosek V, Pilote L, **Proietti M**, Raparelli V; Internal Medicine Assessment of Gender differences IN Europe (IMAGINE) Working group within the European Federation of Internal Medicine (EFIM). Awareness of sex and gender dimensions among physicians: the European federation of internal medicine assessment of gender differences in Europe (EFIM-IMAGINE) survey. *Intern Emerg Med*. 2022 Aug;17(5):1395-1404. doi: 10.1007/s11739-022-02951-9.
13. Imberti JF, Mei DA, Vitolo M, Bonini N, **Proietti M**, Potpara T, Lip GYH, Boriani G. Comparing atrial fibrillation guidelines: Focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations. *Eur J Intern Med*. 2022 Jul;101:1-7. doi: 10.1016/j.ejim.2022.04.023.
14. **Proietti M**, Ntaios G. Anticoagulation for Thromboprophylaxis in Patients with Intracerebral Hemorrhage: Less Room for Skepticism. *Thromb Haemost*. 2022 Jul;122(7):1071-1074. doi: 10.1055/a-1834-4923.
15. Malavasi VL, Vitolo M, **Proietti M**, Diemberger I, Fauchier L, Marin F, Nabauer M, Potpara TS, Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Lane DA, Lip GYH, Boriani G; ESC-EHRA EORP-AF Long-Term General Registry Investigators. Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry. *Eur J Clin Invest*. 2022 Jul;52(7):e13773. doi: 10.1111/eci.13773.
16. Sonaglioni A, Lonati C, Rigamonti E, Viganò M, Nicolosi GL, **Proietti M**, Lombardo M, Harari S. CHA₂DS₂-VASc score stratifies mortality risk in heart failure patients aged 75 years and older with and without atrial fibrillation. *Aging Clin Exp Res*. 2022 Jul;34(7):1707-1720. doi: 10.1007/s40520-022-02107-x.
17. Raparelli V, Nocella C, **Proietti M**, Romiti GF, Corica B, Bartimoccia S, Stefanini L, Lenzi A, Viceconte N, Tanzilli G, Cammisotto V, Pilote L, Cangemi R, Basili S, Carnevale R; EVA Collaborators. Testosterone-to-estradiol ratio and platelet thromboxane release in ischemic heart disease: the EVA project. *J Endocrinol Invest*. 2022 Jul;45(7):1367-1377. doi: 10.1007/s40618-022-01771-0. Epub 2022 Mar 9. PMID: 35262860; PMCID: PMC9184432.
18. Lombardi R, Mura V, Cespiati A, Iuculano F, Sigon G, Pallini G, **Proietti M**, Motta I, Montinaro B, Fiorelli E, Cesari M, Bandera A, Valenti L, Peyvandi F, Montano N, Baldini M, Fracanzani AL. Usefulness of fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity. *Intern Emerg Med*. 2022 Jun 26:1-11. doi: 10.1007/s11739-022-03000-1. Epub ahead of print.
19. Boriani G, Vitolo M, Malavasi VL, **Proietti M**, Fantecchi E, Diemberger I, Fauchier L, Marin F, Nabauer M, Potpara TS, Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Lane DA, Lip GYH; ESC-EHRA EORP-AF Long-Term General Registry Investigators. Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10 220 patients from the ESC-EHRA EORP AF general long-term registry. *Eur J Prev Cardiol*. 2022 Jun 7:zwac115. doi: 10.1093/eurjpc/zwac115. Epub ahead of print.
20. Ding WY, Potpara TS, Blomström-Lundqvist C, Boriani G, Marin F, Fauchier L, Lip GYH; **ESC-EHRA EORP-AF Long-Term General Registry Investigators**. Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry. *Eur J Clin Invest*. 2022 Jun;52(6):e13745. doi: 10.1111/eci.13745.
21. Malavasi VL, Vitolo M, Colella J, Montagnolo F, Mantovani M, **Proietti M**, Potpara TS, Lip GYH, Boriani G. Rhythm- or rate-control strategies according to 4S-AF characterization scheme and long-term outcomes in atrial fibrillation patients: the FAMo (Fibrillazione Atriale in Modena) cohort. *Intern Emerg Med*. 2022 Jun;17(4):1001-1012. doi: 10.1007/s11739-021-02890-x.
22. Alon L, Corica B, Raparelli V, Cangemi R, Basili S, **Proietti M**, Romiti GF. Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. *Eur J Prev Cardiol*. 2022 May 6;29(6):938-946. doi: 10.1093/eurjpc/zwab212.

23. Ding WY, **Proietti M**, Boriani G, Fauchier L, Blomström-Lundqvist C, Marin F, Potpara TS, Lip GYH; ESC-EHRA EORP-AF Long-Term General Registry Investigators. Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry. *Europace*. 2022 May 3;24(5):721-728. doi: 10.1093/europace/euab280.
24. Vitolo M, Malavasi VL, **Proietti M**, Diemberger I, Fauchier L, Marin F, Nabauer M, Potpara TS, Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Lane DA, Lip GYH, Boriani G; ESC-EHRA EORP-AF Long-Term General Registry Investigators. Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry. *Eur J Intern Med*. 2022 May;99:45-56. doi: 10.1016/j.ejim.2022.01.025.
25. Indirli R, Bandera A, Valenti L, Ceriotti F, Di Modugno A, Tettamanti M, Gualtierotti R, Peyvandi F, Montano N, Blasi F, Costantino G, Resi V, Orsi E, Arosio M, Mantovani G, Ferrante E; **COVID-19 Network Working Group**. Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19-hospitalized patients. *Eur J Clin Invest*. 2022 May;52(5):e13753. doi: 10.1111/eci.13753.
26. Sonaglioni A, Lonati C, Tesaro L, Nicolosi GL, **Proietti M**, Lombardo M, Harari S. Prevalence and clinical outcome of main echocardiographic and hemodynamic heart failure phenotypes in a population of hospitalized patients 70 years old and older. *Aging Clin Exp Res*. 2022 May;34(5):1081-1094. doi: 10.1007/s40520-021-02025-4.
27. Bonini N, Vitolo M, Imberti JF, **Proietti M**, Romiti GF, Boriani G, Paaske Johnsen S, Guo Y, Lip GYH. Mobile health technology in atrial fibrillation. *Expert Rev Med Devices*. 2022 Apr;19(4):327-340. doi: 10.1080/17434440.2022.2070005.
28. Corica B, Romiti GF, Basili S, **Proietti M**. Prevalence of New-Onset Atrial Fibrillation and Associated Outcomes in Patients with Sepsis: A Systematic Review and Meta-Analysis. *J Pers Med*. 2022 Mar 30;12(4):547. doi: 10.3390/jpm12040547.
29. **Proietti M**, Camera M, Gallieni M, Gianturco L, Gidaro A, Piemontese C, Pizzetti G, Redaelli F, Scimeca B, Tadeo CS, Cesari M, Bellelli G, Dalla Vecchia LA. Use and Prescription of Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Multidisciplinary Consensus Document. *J Pers Med*. 2022 Mar 15;12(3):469. doi: 10.3390/jpm12030469.
30. Corica B, Romiti GF, Raparelli V, Cangemi R, Basili S, **Proietti M**. Epidemiology of cerebral microbleeds and risk of adverse outcomes in atrial fibrillation: a systematic review and meta-analysis. *Europace*. 2022 Mar 4; euac028. doi: 10.1093/europace/euac028. Epub ahead of print.
31. Romiti GF, Pastori D, Rivera-Caravaca JM, Ding WY, Gue YX, Menichelli D, Gumprecht J, Koziel M, Yang PS, Guo Y, Lip GYH, **Proietti M**. Adherence to the 'Atrial Fibrillation Better Care' Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes-A Systematic Review and Meta-Analysis of 285,000 Patients. *Thromb Haemost*. 2022 Mar;122(3):406-414. doi: 10.1055/a-1515-9630.
32. Malavasi VL, Valenti AC, Ruggerini S, Manicardi M, Orlandi C, Sgreccia D, Vitolo M, **Proietti M**, Lip GYH, Boriani G. Kidney Function According to Different Equations in Patients Admitted to a Cardiology Unit and Impact on Outcome. *J Clin Med*. 2022 Feb 8;11(3):891. doi: 10.3390/jcm11030891.
33. **Proietti M**, Boriani G. Screening for Atrial Fibrillation in Relation to Stroke and Mortality Risk. *Thromb Haemost*. 2022 Feb;122(2):171-175. doi: 10.1055/a-1562-0747.
34. Boriani G, **Proietti M**, Bertini M, Diemberger I, Palmisano P, Baccarini S, Biscione F, Bottoni N, Ciccaglioni A, Dal Monte A, Ferrari FA, Iacopino S, Piacenti M, Porcelli D, Sangiorgio S, Santini L, Malagù M, Stabile G, Imberti JF, Caruso D, Zoni-Berisso M, De Ponti R, Ricci RP, On Behalf Of Ri-Aiac Registry Investigators. Incidence and Predictors of Infections and All-Cause Death in Patients with Cardiac Implantable Electronic Devices: The Italian Nationwide RI-AIAC Registry. *J Pers Med*. 2022 Jan 11;12(1):91. doi: 10.3390/jpm12010091.
35. Calcaterra L, **Proietti M**, Saporiti E, Nunziata V, Rolland Y, Vellas B, Cesari M. Predictors of drug prescription in nursing home residents: results from the INCUR study. *Intern Emerg Med*. 2022 Jan;17(1):165-171. doi: 10.1007/s11739-021-02841-6.
36. **Proietti M**, Vitolo M, Harrison SL, Lane DA, Fauchier L, Marin F, Nabauer M, Potpara TS, Dan GA, Boriani G, Lip GYH; ESC-EHRA EORP-AF Long-Term General Registry Investigators. Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. *Clin Res Cardiol*. 2022 Jan;111(1):70-84. doi: 10.1007/s00392-021-01914-y.
37. Gigante A, **Proietti M**, Petrillo E, Mannucci PM, Nobili A, Muscaritoli M; REPOSI Investigators. Renal Function, Cardiovascular Diseases, Appropriateness of Drug Prescription and Outcomes in Hospitalized Older Patients. *Drugs Aging*. 2021 Dec;38(12):1097-1105. doi: 10.1007/s40266-021-00903-0.

38. Azzolino D, Marzetti E, **Proietti M**, Calvani R, de Souto Barreto P, Rolland Y, Cesari M. Lack of energy is associated with malnutrition in nursing home residents: Results from the INCUR study. *J Am Geriatr Soc*. 2021 Nov;69(11):3242-3248. doi: 10.1111/jgs.17393.
39. **Proietti M**, Vitolo M, Harrison SL, Lane DA, Fauchier L, Marin F, Nabauer M, Potpara TS, Dan GA, Boriani G, Lip GYH; ESC-EHRA EORP-AF Long-Term General Registry Investigators. Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. *BMC Med*. 2021 Oct 20;19(1):256. doi: 10.1186/s12916-021-02120-3.
40. **Proietti M**, Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V, Roldán Rabadán I, Muñoz J, Cequier Á, Bertomeu-Martínez V, Badimón L, Anguita M, Lip GYH, Marín F; FANTASIA Study Investigators. Relationship between multimorbidity and outcomes in atrial fibrillation. *Exp Gerontol*. 2021 Oct 1;153:111482. doi: 10.1016/j.exger.2021.111482.
41. Vitolo M, Imberti JF, Maisano A, Albini A, Bonini N, Valenti AC, Malavasi VL, **Proietti M**, Healey JS, Lip GY, Boriani G. Device-detected atrial high rate episodes and the risk of stroke/thromboembolism and atrial fibrillation incidence: a systematic review and meta-analysis. *Eur J Intern Med*. 2021 Oct;92:100-106. doi: 10.1016/j.ejim.2021.05.038.
42. Falsetti L, Rucco M, **Proietti M**, Viticchi G, Zaccone V, Scarponi M, Giovenali L, Moroncini G, Nitti C, Salvi A. Risk prediction of clinical adverse outcomes with machine learning in a cohort of critically ill patients with atrial fibrillation. *Sci Rep*. 2021 Sep 23;11(1):18925. doi: 10.1038/s41598-021-97218-2.
43. **Proietti M**, Romiti GF, Vitolo M, Potpara TS, Boriani G, Lip GYH. Comparison of HAS-BLED and ORBIT Bleeding Risk Scores in AF Patients treated with NOACs: A Report from the ESC-EHRA EORP-AF General Long-Term Registry. *Eur Heart J Qual Care Clin Outcomes*. 2021 Sep 23:qcab069. doi: 10.1093/ehjqcco/qcab069.
44. Romiti GF, Corica B, Pipitone E, Vitolo M, Raparelli V, Basili S, Boriani G, Harari S, Lip GYH, **Proietti M**; AF-COMET International Collaborative Group. Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients. *Eur Heart J*. 2021 Sep 14;42(35):3541-3554. doi: 10.1093/eurheartj/ehab453.
45. Corica B, Marra AM, Basili S, Cangemi R, Cittadini A, **Proietti M**, Romiti GF. Prevalence of right ventricular dysfunction and impact on all-cause death in hospitalized patients with COVID-19: a systematic review and meta-analysis. *Sci Rep*. 2021 Sep 7;11(1):17774. doi: 10.1038/s41598-021-96955-8.
46. Sgreccia D, Manicardi M, Malavasi VL, Vitolo M, Valenti AC, **Proietti M**, Lip GYH, Boriani G. Comparing Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation: A Systematic Review and Meta-Analysis of 81,462 Patients. *J Clin Med*. 2021 Sep 2;10(17):3979. doi: 10.3390/jcm10173979.
47. **Proietti M**, Cesari M. Describing the relationship between atrial fibrillation and frailty: Clinical implications and open research questions. *Exp Gerontol*. 2021 Sep;152:111455. doi: 10.1016/j.exger.2021.111455.
48. **Proietti M**, Rivera-Caravaca JM, Esteve-Pastor MA, Marín F, Lip GYH. Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores. *Thromb Haemost*. 2021 Aug;121(8):1107-1114. doi: 10.1055/a-1333-4448.
49. Vitolo M, **Proietti M**, Shantsila A, Boriani G, Lip GYH. Clinical Phenotype Classification of Atrial Fibrillation Patients Using Cluster Analysis and Associations with Trial-Adjudicated Outcomes. *Biomedicines*. 2021 Jul 20;9(7):843. doi: 10.3390/biomedicines9070843.
50. Romiti GF, **Proietti M**. Impact of rate control in hospitalized patients with atrial fibrillation and sepsis. *Eur J Intern Med*. 2021 Jul;89:126-128. doi: 10.1016/j.ejim.2021.03.033.
51. Boriani G, Vitolo M, Diemberger I, **Proietti M**, Valenti AC, Malavasi VL, Lip GYH. Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes. *Cardiovasc Res*. 2021 Jun 16;117(7):1-21. doi: 10.1093/cvr/cvab147.
52. Romiti GF, Corica B, Lip GYH, **Proietti M**. Prevalence and Impact of Atrial Fibrillation in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. *J Clin Med*. 2021 Jun 4;10(11):2490. doi: 10.3390/jcm10112490.
53. Marzona I, **Proietti M**, Colacioppo P, Foresta A, Baviera M. Effectiveness and safety of high and low dose NOACs in patients with atrial fibrillation. *Eur J Intern Med*. 2021 Jun;88:118-122. doi: 10.1016/j.ejim.2021.01.031.
54. **Proietti M**, Vitolo M, Lip GYH. Integrated care and outcomes in patients with atrial fibrillation and comorbidities. *Eur J Clin Invest*. 2021 Jun;51(6):e13498. doi: 10.1111/eci.13498.

55. **Proietti M**, Marzona I, Vannini T, Colacioppo P, Tettamanti M, Foresta A, Fortino I, Merlino L, Lip GYH, Roncaglioni MC. Impact of liver disease on oral anticoagulant prescription and major adverse events in patients with atrial fibrillation: analysis from a population-based cohort study. *Eur Heart J Cardiovasc Pharmacother*. 2021 Apr 9;7(F11):f84-f92. doi: 10.1093/ehjcvp/pvaa015.
56. **Proietti M**, Romiti GF. Management of Ventricular Heart Rate in Atrial Fibrillation Patients With Sepsis. *Chest*. 2021 Apr;159(4):1315-1316. doi: 10.1016/j.chest.2020.12.034. Epub 2021 Apr 6. PMID: 34021986.
57. Vitalis A, Shantsila A, **Proietti M**, Vohra RK, Kay M, Olshansky B, Lip GYH. Peripheral Arterial Disease in Patients with Atrial Fibrillation: The AFFIRM Study. *Am J Med*. 2021 Apr;134(4):514-518. doi: 10.1016/j.amjmed.2020.08.026.
58. Romiti GF, Corica B, **Proietti M**. A comprehensive appraisal of dabigatran etexilate clinical evidence and applications: a 10-year-long story. *Future Cardiol*. 2021 Mar;17(2):215-226. doi: 10.2217/fca-2020-0084.
59. Domek M, Gumprecht J, Li YG, **Proietti M**, Rashed W, Al Qudaimi A, Gumprecht J, Zubaid M, Lip GYH. Compliance of atrial fibrillation treatment with the ABC pathway in patients with concomitant diabetes mellitus in the Middle East based on the Gulf SAFE registry. *Eur J Clin Invest*. 2021 Mar;51(3):e13385. doi: 10.1111/eci.13385.
60. **Proietti M**, Lip GYH, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T, Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Boriani G; ESC-EORP Atrial Fibrillation General Long-Term Registry Investigators Group. Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. *Europace*. 2021 Feb 5;23(2):174-183. doi: 10.1093/europace/euaa274.
61. Romiti GF, Corica B, Borgi M, Visioli G, Pacella E, Cangemi R, **Proietti M**, Basili S, Raparelli V. Inherited and acquired thrombophilia in adults with retinal vascular occlusion: A systematic review and meta-analysis. *J Thromb Haemost*. 2020 Dec;18(12):3249-3266. doi: 10.1111/jth.15068.
62. Bandera A, Aliberti S, Gualtierotti R, Baldini M, Blasi F, Cesari M, Costantino G, Fracanzani AL, Gori A, Montano N, Monzani V, Nobili A, Peyvandi F, Pesenti A, Prati D, Valenti L, Fusetti G, Scudeller L, Bosari S; **COVID-19 Network**; Scientific Direction; Department of Transfusion Medicine and Biobank; Infectious Diseases Unit; Internal Medicine, Hemophilia and Thrombosis Center and Fondazione Luigi Villa; Internal Medicine, Immunology and Allergies; Respiratory Unit and Cystic Fibrosis Adult Center; Cardiology Unit; Emergency Medicine; Acute Internal Medicine; Internal Medicine; Internal Medicine and Metabolic Diseases; Geriatric Unit; Istituto di Ricerche Farmacologiche Mario Negri IRCCS. COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemic. *Clin Microbiol Infect*. 2020 Nov;26(11):1576-1578. doi: 10.1016/j.cmi.2020.06.028.
63. Falsetti L, **Proietti M**, Zacccone V, Guerra F, Nitti C, Salvi A, Viticchi G, Riccomi F, Sampaolesi M, Silvestrini M, Moroncini G, Lip GYH, Capucci A. Impact of atrial fibrillation in critically ill patients admitted to a stepdown unit. *Eur J Clin Invest*. 2020 Nov;50(11):e13317. doi: 10.1111/eci.13317.
64. Vitolo M, **Proietti M**, Harrison S, Lane DA, Potpara TS, Boriani G, Lip GYH. The Euro Heart Survey and EURObservational Research Programme (EORP) in atrial fibrillation registries: contribution to epidemiology, clinical management and therapy of atrial fibrillation patients over the last 20 years. *Intern Emerg Med*. 2020 Oct;15(7):1183-1192. doi: 10.1007/s11739-020-02405-0.
65. Corsini A, Ferri N, **Proietti M**, Boriani G. Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. *Drugs*. 2020 Jul;80(11):1065-1083. doi: 10.1007/s40265-020-01328-6.
66. **Proietti M**, Romiti GF, Olshansky B, Lane DA, Lip GYH. Comprehensive Management With the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients With Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM Trial. *J Am Heart Assoc*. 2020 May 18;9(10):e014932. doi: 10.1161/JAHA.119.014932.
67. Cesari M, **Proietti M**. COVID-19 in Italy: Ageism and Decision Making in a Pandemic. *J Am Med Dir Assoc*. 2020 May;21(5):576-577. doi: 10.1016/j.jamda.2020.03.025.
68. **Proietti M**, Vitolo M, Boriani G. Tailored oral anticoagulant prescription in patients with atrial fibrillation: Use and misuse of clinical risk prediction scores. *Eur J Prev Cardiol*. 2020 May;27(7):726-728. doi: 10.1177/2047487319877469.
69. Gumprecht J, Domek M, **Proietti M**, Li YG, Asaad N, Rashed W, Alsheikh-Ali A, Zubaid M, Lip GYH. Compliance of Atrial Fibrillation Treatment with the Atrial Fibrillation Better Care (ABC) Pathway Improves the Clinical Outcomes in the Middle East Population: A Report from the Gulf

- Survey of Atrial Fibrillation Events (SAFE) Registry. *J Clin Med*. 2020 Apr 29;9(5):1286. doi: 10.3390/jcm9051286.
70. Imberti JF, Vitolo M, **Proietti M**, Diemberger I, Ziacchi M, Biffi M, Boriani G. Driving restriction in patients with cardiac implantable electronic devices: an overview of worldwide regulations. *Expert Rev Med Devices*. 2020 Apr;17(4):297-308. doi: 10.1080/17434440.2020.1742108.
 71. **Proietti M**, Boriani G. Obesity Paradox in Atrial Fibrillation: Implications for Outcomes and Relationship with Oral Anticoagulant Drugs. *Am J Cardiovasc Drugs*. 2020 Apr;20(2):125-137. doi: 10.1007/s40256-019-00374-0.
 72. **Proietti M**, Farcomeni A, Romiti GF, Di Rocco A, Placentino F, Diemberger I, Lip GY, Boriani G. Association between clinical risk scores and mortality in atrial fibrillation: Systematic review and network meta-regression of 669,000 patients. *Eur J Prev Cardiol*. 2020 Apr;27(6):633-644. doi: 10.1177/2047487318817662.
 73. Romiti GF, Basili S, **Proietti M**. Antithrombotic treatment strategies after PCI. *Lancet*. 2020 Mar 14;395(10227):866. doi: 10.1016/S0140-6736(20)30031-3.
 74. Raparelli V, Romiti GF, Spugnardi V, Borgi M, Cangemi R, Basili S, **Proietti M**; The Eva Collaborative Group. Gender-Related Determinants of Adherence to the Mediterranean Diet in Adults with Ischemic Heart Disease. *Nutrients*. 2020 Mar 13;12(3):759. doi: 10.3390/nu12030759.
 75. **Proietti M**, Lane DA. The Compelling Issue of Nonvitamin K Antagonist Oral Anticoagulant Adherence in Atrial Fibrillation Patients: A Systematic Need for New Strategies. *Thromb Haemost*. 2020 Mar;120(3):369-371. doi: 10.1055/s-0040-1702231.
 76. **Proietti M**. Management of peripheral arterial disease in the modern era: an internist "Cup of Tea". *Intern Emerg Med*. 2020 Mar;15(2):195-197. doi: 10.1007/s11739-019-02236-8.
 77. Marzona I, **Proietti M**, Vannini T, Tettamanti M, Nobili A, Medaglia M, Bortolotti A, Merlino L, Roncaglioni MC. Sex-related differences in prevalence, treatment and outcomes in patients with atrial fibrillation. *Intern Emerg Med*. 2020 Mar;15(2):231-240. doi: 10.1007/s11739-019-02134-z.
 78. Raparelli V, **Proietti M**, Lenzi A, Basili S; EVA Collaborators. Sex and Gender Differences in Ischemic Heart Disease: Endocrine Vascular Disease Approach (EVA) Study Design. *J Cardiovasc Transl Res*. 2020 Feb;13(1):14-25. doi: 10.1007/s12265-018-9846-5.
 79. Nunziata V, **Proietti M**, Saporiti E, Calcaterra L, Rolland Y, Vellas B, Cesari M. Pain Management in Nursing Home Residents: Results from the INCUR Study. *J Nutr Health Aging*. 2020;24(9):1019-1022. doi: 10.1007/s12603-020-1443-z.
 80. Azzolino D, Saporiti E, **Proietti M**, Cesari M. Nutritional Considerations in Frail Older Patients with COVID-19. *J Nutr Health Aging*. 2020;24(7):696-698. doi: 10.1007/s12603-020-1400-x.
 81. Cesari M, **Proietti M**. Editorial: Geriatric medicine in Italy in the time of COVID-19. *J Nutr Health Aging*. 2020;24(5):459-460. doi: 10.1007/s12603-020-1354-z.
 82. **Proietti M**, Cesari M. Frailty: What Is It? *Adv Exp Med Biol*. 2020;1216:1-7. doi: 10.1007/978-3-030-33330-0_1.
 83. Potpara TS, Mujovic N, **Proietti M**, Dagres N, Hindricks G, Collet JP, Valgimigli M, Heidbuchel H, Lip GYH. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. *Europace*. 2020 Jan 1;22(1):33-46. doi: 10.1093/europace/euz259.
 84. **Proietti M**, Marzona I, Vannini T, Tettamanti M, Fortino I, Merlino L, Basili S, Mannucci PM, Boriani G, Lip GYH, Roncaglioni MC, Nobili A. Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use. *Mayo Clin Proc*. 2019 Dec;94(12):2427-2436. doi: 10.1016/j.mayocp.2019.06.012.
 85. **Proietti M**. Managing thromboembolic risk in patients with subclinical atrial fibrillation: A new challenge for the clinical cardiologist. *Int J Cardiol*. 2019 Dec 1;296:89-90. doi: 10.1016/j.ijcard.2019.08.047.
 86. Malavasi VL, **Proietti M**, Spagni S, Valenti AC, Battista A, Pettorelli D, Colella J, Vitolo M, Lip GY, Boriani G. Usefulness of Red Cells Distribution Width to Predict Worse Outcomes in Patients With Atrial Fibrillation. *Am J Cardiol*. 2019 Nov 15;124(10):1561-1567. doi: 10.1016/j.amjcard.2019.08.008.
 87. Marra AM, **Proietti M**, Bossone E, Salzano A, Cittadini A. Risk stratification in hospitalized heart failure patients: do the RIGHT thing! *Intern Emerg Med*. 2019 Oct;14(7):1021-1023. doi: 10.1007/s11739-019-02121-4. Epub 2019 Jun 18. PMID: 31214885.
 88. **Proietti M**, Agosti P, Lonati C, Corrao S, Perticone F, Mannucci PM, Nobili A, Harari S; REPOSI Investigators. Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids. *J Am Med Dir Assoc*. 2019 Oct;20(10):1313-1317.e9. doi: 10.1016/j.jamda.2019.01.132.

89. Lowres N, Olivier J, Chao TF, Chen SA, Chen Y, Diederichsen A, Fitzmaurice DA, Gomez-Doblas JJ, Harbison J, Healey JS, Hobbs FDR, Kaasenbrood F, Keen W, Lee VW, Lindholt JS, Lip GYH, Mairesse GH, Mant J, Martin JW, Martín-Rioboó E, McManus DD, Muñiz J, Münzel T, Nakamya J, Neubeck L, Orchard JJ, Pérula de Torres LÁ, **Proietti M**, Quinn FR, Roalfe AK, Sandhu RK, Schnabel RB, Smyth B, Soni A, Tieleman R, Wang J, Wild PS, Yan BP, Freedman B. Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-level meta-analysis of 141,220 screened individuals. *PLoS Med*. 2019 Sep 25;16(9):e1002903. doi: 10.1371/journal.pmed.1002903.
90. Boriani G, **Proietti M**. Screening for atrial fibrillation: Need for an integrated, structured approach. *Eur J Intern Med*. 2019 Sep;67:33-35. doi: 10.1016/j.ejim.2019.07.017.
91. Antoniazzi S, Ardoino I, **Proietti M**, Monzani V, Mannucci PM, Nobili A, Franchi C; SIM-AF Collaborators. Appropriateness of prescription of oral anticoagulant therapy in acutely hospitalized older people with atrial fibrillation. Secondary analysis of the SIM-AF cluster randomized clinical trial. *Br J Clin Pharmacol*. 2019 Sep;85(9):2134-2142. doi: 10.1111/bcp.14029.
92. Franchi C, Antoniazzi S, Ardoino I, **Proietti M**, Marcucci M, Santalucia P, Monzani V, Mannucci PM, Nobili A; SIM-AF Collaborators. Simulation-Based Education for Physicians to Increase Oral Anticoagulants in Hospitalized Elderly Patients with Atrial Fibrillation. *Am J Med*. 2019 Aug;132(8):e634-e647. doi: 10.1016/j.amjmed.2019.03.052.
93. Boriani G, **Proietti M**, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T, Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Lip GYH; EORP-AF Long-Term General Registry Investigators. Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. *Europace*. 2019 Jul 1;21(7):1013-1022. doi: 10.1093/europace/euz032.
94. Marra AM, **Proietti M**. Diuretic resistance in decompensated chronic heart failure: trying to get out of the "loop". *Intern Emerg Med*. 2019 Jun;14(4):497-498. doi: 10.1007/s11739-019-02083-7.
95. **Proietti M**, Farcomeni A, Goethals P, Scavee C, Vijgen J, Blankoff I, Vandekerckhove Y, Lip GY, Mairesse GH; Belgian Heart Rhythm Week Investigators. Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme. *Eur J Prev Cardiol*. 2019 Jun;26(9):964-972. doi: 10.1177/2047487319839184.
96. **Proietti M**, Lane DA, Boriani G, Lip GYH. Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. *Can J Cardiol*. 2019 May;35(5):619-633. doi: 10.1016/j.cjca.2019.02.009.
97. Boriani G, Vitolo M, **Proietti M**. Cardiomyopathy associated with long-term right ventricular pacing: an intriguing clinical issue. *Eur J Heart Fail*. 2019 May;21(5):652-654. doi: 10.1002/ejhf.1449.
98. Raparelli V, **Proietti M**, Romiti GF, Lenzi A, Basili S; EVA Collaborative Group. The Sex-Specific Detrimental Effect of Diabetes and Gender-Related Factors on Pre-admission Medication Adherence Among Patients Hospitalized for Ischemic Heart Disease: Insights From EVA Study. *Front Endocrinol (Lausanne)*. 2019 Feb 25;10:107. doi: 10.3389/fendo.2019.00107.
99. Salzano A, Marra AM, **Proietti M**, Raparelli V, Heaney LM. Biomarkers in Heart Failure and Associated Diseases. *Dis Markers*. 2019 Feb 7;2019:8768624. doi: 10.1155/2019/8768624.
100. Romiti GF, Cangemi R, Toriello F, Ruscio E, Sciomer S, Moscucci F, Vincenti M, Crescioli C, **Proietti M**, Basili S, Raparelli V. Sex-Specific Cut-Offs for High-Sensitivity Cardiac Troponin: Is Less More? *Cardiovasc Ther*. 2019 Feb 5;2019:9546931. doi: 10.1155/2019/9546931.
101. Alexander KP, Brouwer MA, Mulder H, Vinereanu D, Lopes RD, **Proietti M**, Al-Khatib SM, Hijazi Z, Halvorsen S, Hylek EM, Verheugt FWA, Alexander JH, Wallentin L, Granger CB; ARISTOTLE Investigators. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. *Am Heart J*. 2019 Feb;208:123-131. doi: 10.1016/j.ahj.2018.09.017.
102. **Proietti M**. Impact of hospitalization in patients with atrial fibrillation: Implications for health-care providers and clinical management. *Int J Cardiol*. 2019 Feb 1;276:287-288. doi: 10.1016/j.ijcard.2018.10.065.
103. Boriani G, Fauchier L, Aguinaga L, Beattie JM, Blomstrom Lundqvist C, Cohen A, Dan GA, Genovesi S, Israel C, Joung B, Kalarus Z, Lampert R, Malavasi VL, Mansourati J, Mont L, Potpara T, Thornton A, Lip GYH; **ESC Scientific Document Group**. European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin

- American Heart Rhythm Society (LAHRS). *Europace*. 2019 Jan 1;21(1):7-8. doi: 10.1093/europace/euy110. PMID: 29905786.
104. **Proietti M**, Mujovic N, Potpara TS. Optimizing Stroke and Bleeding Risk Assessment in Patients with Atrial Fibrillation: A Balance of Evidence, Practicality and Precision. *Thromb Haemost*. 2018 Dec;118(12):2014-2017. doi: 10.1055/s-0038-1676074.
 105. Peñaloza-Martínez E, Demelo-Rodríguez P, **Proietti M**, Soria Fernández-Llamazares G, Llamazares-Mendo C, Álvarez-Sala Walther L, Marra AM, Del Toro-Cervera J. Update on extended treatment for venous thromboembolism. *Ann Med*. 2018 Dec;50(8):666-674. doi: 10.1080/07853890.2018.1538564.
 106. Raparelli V, **Proietti M**, Basili S. Explanatory power of gender relations in cardiovascular outcomes: the missing piece of the puzzle. *Heart*. 2018 Dec;104(23):1900-1901. doi: 10.1136/heartjnl-2018-313469.
 107. **Proietti M**. Evolving concepts in atrial fibrillation epidemiology: Advancing knowledge about cardiovascular health in sub-Saharan Africa. *Int J Cardiol*. 2018 Nov 15;271:115-116. doi: 10.1016/j.ijcard.2018.07.006.
 108. Boriani G, **Proietti M**, Laroche C, Diemberger I, Popescu MI, Riahi S, Shantsila A, Dan GA, Tavazzi L, Maggioni AP, Lip GYH; EORP-AF Pilot General Registry Investigators. Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) pilot general registry. *Int J Cardiol*. 2018 Nov 15;271:68-74. doi: 10.1016/j.ijcard.2018.05.034.
 109. **Proietti M**, Romiti GF, Olshansky B, Lane DA, Lip GYH. Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. *Am J Med*. 2018 Nov;131(11):1359-1366.e6. doi: 10.1016/j.amjmed.2018.06.012.
 110. Marzona I, **Proietti M**, Farcomeni A, Romiti GF, Romanazzi I, Raparelli V, Basili S, Lip GYH, Nobili A, Roncaglioni MC. Sex differences in stroke and major adverse clinical events in patients with atrial fibrillation: A systematic review and meta-analysis of 993,600 patients. *Int J Cardiol*. 2018 Oct 15;269:182-191. doi: 10.1016/j.ijcard.2018.07.044.
 111. **Proietti M**, Rivera-Caravaca JM, Esteve-Pastor MA, Romiti GF, Marin F, Lip GYH. Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS-BLED and GARFIELD-AF Bleeding Scores. *J Am Heart Assoc*. 2018 Sep 18;7(18):e009766. doi: 10.1161/JAHA.118.009766.
 112. Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V, Orenes-Piñero E, Romiti GF, Romanazzi I, Bai Y, Carmo J, **Proietti M**, Marin F, Lip GYH. Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation. *Am J Cardiol*. 2018 Sep 1;122(5):785-792. doi: 10.1016/j.amjcard.2018.05.012.
 113. **Proietti M**, Laroche C, Nieuwlaet R, Crijns HJGM, Maggioni AP, Lane DA, Boriani G, Lip GYH; EORP-AF General Pilot Registry; Euro Heart Survey on AF Investigators. Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. *Eur J Intern Med*. 2018 Sep;55:28-34. doi: 10.1016/j.ejim.2018.05.016.
 114. Franchi C, Antoniazzi S, **Proietti M**, Nobili A, Mannucci PM; SIM-AF Collaborators. Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation. *Br J Clin Pharmacol*. 2018 Sep;84(9):2010-2019. doi: 10.1111/bcp.13631.
 115. Dagres N, Chao TF, Fenelon G, Aguinaga L, Benhayon D, Benjamin EJ, Bunch TJ, Chen LY, Chen SA, Darrieux F, de Paola A, Fauchier L, Goette A, Kalman J, Kalra L, Kim YH, Lane DA, Lip GYH, Lubitz SA, Márquez MF, Potpara T, Pozzer DL, Ruskin JN, Savelieva I, Teo WS, Tse HF, Verma A, Zhang S, Chung MK; **ESC Scientific Document Group**. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice? *Europace*. 2018 Sep 1;20(9):1399-1421. doi: 10.1093/europace/euy046.
 116. **Proietti M**, Boriani G. Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal. *Ther Clin Risk Manag*. 2018 Aug 22;14:1483-1488. doi: 10.2147/TCRM.S140377.
 117. Gigante A, Rosato E, **Proietti M**, Cianci R, Di Lazzaro-Giraldi G, Tubani L; HRV Study Group. Heart rate variability in nephrotic syndrome: Role of sympathetic and parasympathetic system. *Eur J Intern Med*. 2018 Aug;54:e21-e22. doi: 10.1016/j.ejim.2018.05.002.
 118. Raparelli V, Pastori D, Pignataro SF, Vestri AR, Pignatelli P, Cangemi R, **Proietti M**, Davì G, Hiatt WR, Lip GYH, Corazza GR, Perticone F, Violi F, Basili S; ARAPACIS Study Collaborators. Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive

- pulmonary disease: the ARAPACIS study. *Intern Emerg Med*. 2018 Aug;13(5):651-660. doi: 10.1007/s11739-018-1835-9.
119. **Proietti M**, Lane DA. Use of NOACs in the Peri-Operative Management of Patients with Atrial Fibrillation: To Stop, Bridge or Continue? *Thromb Haemost*. 2018 Jul;118(7):1123-1126. doi: 10.1055/s-0038-1661370.
 120. **Proietti M**, Romiti GF, Romanazzi I, Farcomeni A, Staerk L, Nielsen PB, Lip GYH. Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: A systematic review and meta-analysis. *Int J Cardiol*. 2018 Jun 15;261:84-91. doi: 10.1016/j.ijcard.2018.03.053.
 121. **Proietti M**, Antoniazzi S, Monzani V, Santalucia P, Franchi C; SIM-AF Investigators, Fenoglio LM, Melchio R, Fabris F, Sartori MT, Manfredini R, De Giorgi A, Fabbian F, Biolo G, Zanetti M, Altamura N, Sabbà C, Suppressa P, Bandiera F, Usai C, Murialdo G, Fezza F, Marra A, Castelli F, Cattaneo F, Beccati V, di Minno G, Tufano A, Contaldi P, Lupattelli G, Bianconi V, Cappellini D, Hu C, Minonzio F, Fargion S, Burdick L, Francione P, Peyvandi F, Rossio R, Colombo G, Monzani V, Ceriani G, Lucchi T, Brignolo B, Manfellotto D, Caridi I, Corazza GR, Miceli E, Padula D, Fraternali G, Guasti L, Squizzato A, Maresca A, Liberato NL, Tognin T, Rozzini R, Bellucci FB, Muscaritoli M, Molfino A, Petrillo E, Dore M, Mete F, Gino M, Franceschi F, Gabrielli M, Perticone F, Perticone M, Bertolotti M, Mussi C, Borghi C, Strocchi E, Durazzo M, Fornengo P, Dallegri F, Ottonello LC, Salam K, Caserza L, Barbagallo M, Di Bella G, Annoni G, Bruni AA, Odetti P, Nencioni A, Monacelli F, Napolitano A, Brucato A, Valenti A, Castellino P, Zanolli L, Mazzeo M. Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards. *Eur J Intern Med*. 2018 Jun;52:e12-e14. doi: 10.1016/j.ejim.2018.04.006.
 122. Gigante A, Zingaretti V, **Proietti M**, Rosato E, Cianci R; HRV Study Group. Autonomic dysfunction and cardiovascular risk in patients with atherosclerotic renal artery stenosis: A pilot study. *Eur J Intern Med*. 2018 Jun;52:e19-e21. doi: 10.1016/j.ejim.2018.03.002.
 123. Boriani G, **Proietti M**. Atrial fibrillation prevention: an appraisal of current evidence. *Heart*. 2018 Jun;104(11):882-887. doi: 10.1136/heartjnl-2017-311546.
 124. Barbano B, Gigante A, **Proietti M**, Rosato E, Cianci R. Impact of revascularization procedures on Doppler parameters in patients with atherosclerotic renal artery stenosis. *Eur J Intern Med*. 2018 May;51:e28-e29. doi: 10.1016/j.ejim.2018.02.002.
 125. Boriani G, **Proietti M**, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T, Dan GA, Kalarus Z, Diemberger I, Tavazzi L, Maggioni AP, Lip GYH; EORP-AF Long-Term General Registry Investigators; Steering Committee (National Coordinators). Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. *Europace*. 2018 May 1;20(5):747-757. doi: 10.1093/europace/eux301.
 126. **Proietti M**, Farcomeni A. Association Between Peripheral Artery Disease and Incident Risk of Atrial Fibrillation: Strong Evidence Coming From Population-Based Cohort Studies. *J Am Heart Assoc*. 2018 Apr 17;7(8):e009126. doi: 10.1161/JAHA.118.009126.
 127. Dagues N, Chao TF, Fenelon G, Aguinaga L, Benhayon D, Benjamin EJ, Bunch TJ, Chen LY, Chen SA, Darrieux F, de Paola A, Fauchier L, Goette A, Kalman J, Kalra L, Kim YH, Lane DA, Lip GYH, Lubitz SA, Márquez MF, Potpara T, Pozzer DL, Ruskin JN, Savelieva I, Teo WS, Tse HF, Verma A, Zhang S, Chung MK, Bautista-Vargas WF, Chiang CE, Cuesta A, Dan GA, Frankel DS, Guo Y, Hatala R, Lee YS, Murakawa Y, Pellegrini CN, Pinho C, Milan DJ, Morin DP, Nadalin E, Ntaios G, Prabhu MA, **Proietti M**, Rivard L, Valentino M, Shantsila A. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice? *J Arrhythm*. 2018 Mar 23;34(2):99-123. doi: 10.1002/joa3.12050.
 128. Paciullo F, **Proietti M**, Bianconi V, Nobili A, Pirro M, Mannucci PM, Lip GYH, Lupattelli G; REPOSI Investigators. Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study. *Drugs Aging*. 2018 Apr;35(4):365-373. doi: 10.1007/s40266-018-0532-8.
 129. Boriani G, Laroche C, Diemberger I, Fantecchi E, Meeder J, Kurpesa M, Baluta MM, **Proietti M**, Tavazzi L, Maggioni AP, Lip GYH; EORP-AF General Pilot Registry Investigators. Overweight and obesity in patients with atrial fibrillation: Sex differences in 1-year outcomes in the EORP-AF General Pilot Registry. *J Cardiovasc Electrophysiol*. 2018 Apr;29(4):566-572. doi: 10.1111/jce.13428.
 130. **Proietti M**. The dangerous combination of atrial fibrillation and hypertension: An urgent need to handle complexity. *Int J Cardiol*. 2018 Mar 1;254:167-169. doi: 10.1016/j.ijcard.2017.12.036.
 131. Basili S, Raparelli V, Napoleone L, Talerico G, Corazza GR, Perticone F, Sacerdoti D, Andriulli A, Licata A, Pietrangelo A, Picardi A, Raimondo G, Violi F; **PRO-LIVER Collaborators**. Platelet Count

- Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study. *Am J Gastroenterol*. 2018 Mar;113(3):368-375. doi: 10.1038/ajg.2017.457.
132. Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V, Vicente V, Romiti GF, Romanazzi I, **Proietti M**, Valdés M, Marín F, Lip GYH. Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in 'real-world' atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. *Int J Cardiol*. 2018 Mar 1;254:125-131. doi: 10.1016/j.ijcard.2017.11.087.
 133. **Proietti M**, Hijazi Z, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Lane DA, Oldgren J, Roldan V, Yusuf S, Wallentin L; RE-LY Investigators. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial. *J Intern Med*. 2018 Mar;283(3):282-292. doi: 10.1111/joim.12702.
 134. **Proietti M**, Lip GYH. Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials. *Int J Cardiol*. 2018 Feb 1;252:96-100. doi: 10.1016/j.ijcard.2017.10.091.
 135. Salzano A, **Proietti M**, D'Assante R, Saldamarco L, Cittadini A, Paladino F. Bleeding related to non-vitamin K antagonist oral anticoagulants in emergency department: A "Real-world" snapshot from Southern Italy. On behalf of MIRC-NOAC study group. *Eur J Intern Med*. 2018 Feb;48:e21-e24. doi: 10.1016/j.ejim.2017.10.018.
 136. Purmah Y, **Proietti M**, Laroche C, Mazurek M, Tahmatzidis D, Boriani G, Novo S, Lip GYH; EORP-AF General Pilot Registry Investigators. Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation. *Europace*. 2018 Feb 1;20(2):243-252. doi: 10.1093/europace/euw421.
 137. **Proietti M**, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. *Stroke*. 2018 Jan;49(1):98-106. Doi: 10.1161/STROKEAHA.117.018395.
 138. Lahtela HM, Bah A, Kiviniemi T, Nammas W, Schlitt A, Rubboli A, Karjalainen PP, **Proietti M**, Hartikainen JEK, Lip GYH, Airaksinen KEJ. Outcome of octogenarians with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. *Clin Cardiol*. 2017 Dec;40(12):1264-1270. doi: 10.1002/clc.22821.
 139. **Proietti M**, Laroche C, Nyvad O, Haberka M, Vassilikos VP, Maggioni AP, Boriani G, Lip GYH; EORP-AF Pilot Investigators. Use of statins and adverse outcomes in patients with atrial fibrillation: An analysis from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) general registry pilot phase. *Int J Cardiol*. 2017 Dec 1;248:166-172. doi: 10.1016/j.ijcard.2017.08.055.
 140. **Proietti M**, Recchia A, Riva E, Lucca U, Tettamanti M, Mannucci PM, Nobili A. Relationship between atrial fibrillation and cognitive decline in individuals aged 80 and older. *Eur J Intern Med*. 2017 Dec;46:6-10. doi: 10.1016/j.ejim.2017.08.010.
 141. **Proietti M**, Romiti GF, Olshansky B, Lip GYH. Systolic Blood Pressure Visit-to-Visit Variability and Major Adverse Outcomes in Atrial Fibrillation: The AFFIRM Study (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). *Hypertension*. 2017 Nov;70(5):949-958. doi: 10.1161/HYPERTENSIONAHA.117.10106.
 142. **Proietti M**, Raparelli V, Laroche C, Dan GA, Janion M, Popescu R, Sinagra G, Vijgen J, Boriani G, Maggioni AP, Tavazzi L, Lip GYH; EORP-AF Gen Pilot Investigators. Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation. *Europace*. 2017 Sep 1;19(9):1439-1448. doi: 10.1093/europace/euw169.
 143. Mazurek M, Shantsila E, Lane DA, Wolff A, **Proietti M**, Lip GYH. Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients With Atrial Fibrillation: Insights From the Community-Based Darlington Atrial Fibrillation Registry. *Mayo Clin Proc*. 2017 Aug;92(8):1203-1213. doi: 10.1016/j.mayocp.2017.05.023. PMID: 28778255.
 144. **Proietti M**, Airaksinen KEJ, Rubboli A, Schlitt A, Kiviniemi T, Karjalainen PP, Lip GY; AFCAS Study Group. Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry. *Am Heart J*. 2017 Aug;190:86-93. doi: 10.1016/j.ahj.2017.05.016.
 145. Mazurek M, Shantsila E, Lane DA, Wolff A, **Proietti M**, Lip GYH. Secondary Versus Primary Stroke Prevention in Atrial Fibrillation: Insights From the Darlington Atrial Fibrillation Registry. *Stroke*. 2017 Aug;48(8):2198-2205. doi: 10.1161/STROKEAHA.116.016146. Epub 2017 Jul 5. PMID: 28679859.

146. Sansone A, Sansone M, **Proietti M**, Ciocca G, Lenzi A, Jannini EA, Romanelli F. Relationship Between Use of Videogames and Sexual Health in Adult Males. *J Sex Med.* 2017 Jul;14(7):898-903. doi: 10.1016/j.jsxm.2017.05.001.
147. Basili S, **Proietti M**, Raparelli V. Moving Beyond Traditional Cardiovascular Risk Factors Toward Gendered Horizon. *J Womens Health (Larchmt).* 2017 Jun;26(6):600-601. doi: 10.1089/jwh.2017.6383.
148. **Proietti M**, Lip GY. Geographical differences in thromboembolic and bleeding risks in patients with non-valvular atrial fibrillation: An ancillary analysis from the SPORTIF trials. *Int J Cardiol.* 2017 Jun 1;236:244-248. doi: 10.1016/j.ijcard.2017.02.127.
149. **Proietti M**, Airaksinen KEJ, Rubboli A, Schlitt A, Kiviniemi T, Karjalainen PP, Lip GYH; AFCAS Study Group. Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry. *Clin Res Cardiol.* 2017 Jun;106(6):420-427. doi: 10.1007/s00392-016-1071-0.
150. **Proietti M**, Laroche C, Opolski G, Maggioni AP, Boriani G, Lip GYH; AF Gen Pilot Investigators. 'Real-world' atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase. *Europace.* 2017 May 1;19(5):722-733. doi: 10.1093/europace/euw112.
151. **Proietti M**, Boriani G, Laroche C, Diemberger I, Popescu MI, Rasmussen LH, Sinagra G, Dan GA, Maggioni AP, Tavazzi L, Lane DA, Lip GYH; EORP-AF General Pilot Registry Investigators. Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. *Europace.* 2017 Apr 1;19(4):535-543. doi: 10.1093/europace/euw150.
152. **Proietti M**, Guiducci E, Cheli P, Lip GY. Is There an Obesity Paradox for Outcomes in Atrial Fibrillation? A Systematic Review and Meta-Analysis of Non-Vitamin K Antagonist Oral Anticoagulant Trials. *Stroke.* 2017 Apr;48(4):857-866. doi: 10.1161/STROKEAHA.116.015984.
153. Basili S, Loffredo L, Pastori D, **Proietti M**, Farcomeni A, Vestri AR, Pignatelli P, Davi G, Hiatt WR, Lip GY, Corazza GR, Perticone F, Violi F; in collaboration with ARAPACIS Study Investigators. Carotid plaque detection improves the predictive value of CHA₂DS₂-VASC score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. *Int J Cardiol.* 2017 Mar 15;231:143-149. doi: 10.1016/j.ijcard.2017.01.001.
154. **Proietti M**, Cheli P, Basili S, Mazurek M, Lip GY. Balancing thromboembolic and bleeding risk with non-vitamin K antagonist oral anticoagulants (NOACs): A systematic review and meta-analysis on gender differences. *Pharmacol Res.* 2017 Mar;117:274-282. doi: 10.1016/j.phrs.2017.01.004.
155. **Proietti M**, Mairesse GH, Goethals P, Scavee C, Vijgen J, Blankoff I, Vandekerckhove Y, Lip GY; Belgian Heart Rhythm Week Investigators. Cerebrovascular disease, associated risk factors and antithrombotic therapy in a population screening cohort: Insights from the Belgian Heart Rhythm Week programme. *Eur J Prev Cardiol.* 2017 Feb;24(3):328-334. doi: 10.1177/2047487316682349.
156. Raparelli V, **Proietti M**, Cangemi R, Lip GY, Lane DA, Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. *Thromb Haemost.* 2017 Jan 26;117(2):209-218. doi: 10.1160/TH16-10-0757.
157. Salzano A, Demelo-Rodriguez P, Marra AM, **Proietti M**. A Focused Review of Gender Differences in Antithrombotic Therapy. *Curr Med Chem.* 2017;24(24):2576-2588. doi: 10.2174/0929867323666161029223512.
158. **Proietti M**, Mairesse GH, Goethals P, Scavee C, Vijgen J, Blankoff I, Vandekerckhove Y, Lip GY; Belgian Heart Rhythm Week Investigators. A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme. *Europace.* 2016 Dec;18(12):1779-1786. doi: 10.1093/europace/euw069.
159. **Proietti M**, Laroche C, Drozd M, Vijgen J, Cozma DC, Drozd J, Maggioni AP, Boriani G, Lip GY; EORP-AF Investigators. Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. *Am Heart J.* 2016 Nov;181:83-91. doi: 10.1016/j.ahj.2016.08.011.
160. **Proietti M**, Nobili A, Raparelli V, Napoleone L, Mannucci PM, Lip GY; REPOSI investigators. Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study. *Clin Res Cardiol.* 2016 Nov;105(11):912-920. doi: 10.1007/s00392-016-0999-4.
161. **Proietti M**, Lip GY. Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range Observations from the SPORTIF Trials. *Am J Med.* 2016 Oct;129(10):1110-6. doi: 10.1016/j.amjmed.2016.03.024.

162. Lau YC, **Proietti M**, Guiducci E, Blann AD, Lip GYH. Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease. *J Am Coll Cardiol*. 2016 Sep 27;68(13):1452-1464. doi: 10.1016/j.jacc.2016.06.057.
163. **Proietti M**, Lane DA, Lip GY. Relation of the SAME-TT2R2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials. *Int J Cardiol*. 2016 Aug 1;216:168-72. doi: 10.1016/j.ijcard.2016.04.131.
164. **Proietti M**, Lane DA, Lip GY. Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials). *Am J Cardiol*. 2016 Jul 1;118(1):72-8. doi: 10.1016/j.amjcard.2016.04.013.
165. **Proietti M**, Lane DA, Lip GYH. Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. *EBioMedicine*. 2016 Jun;8:309-316. doi: 10.1016/j.ebiom.2016.04.013.
166. Senoo K, **Proietti M**, Lane DA, Lip GY. Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. *Am J Med*. 2016 Jun;129(6):600-7. doi: 10.1016/j.amjmed.2015.10.001.
167. **Proietti M**, Lip GY. Atrial Fibrillation and Stroke: Making Sense of Recent Observations on Anticoagulation. *Cardiol Clin*. 2016 May;34(2):317-28. doi: 10.1016/j.ccl.2015.12.006.
168. **Proietti M**, Raparelli V, Olshansky B, Lip GY. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. *Clin Res Cardiol*. 2016 May;105(5):412-20. doi: 10.1007/s00392-015-0936-y.
169. **Proietti M**, Senoo K, Lane DA, Lip GY. Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. *Sci Rep*. 2016 Apr 12;6:24376. doi: 10.1038/srep24376. PMID: 27067661; PMCID: PMC4828703.
170. Violi F, Davì G, **Proietti M**, Pastori D, Hiatt WR, Corazza GR, Perticone F, Pignatelli P, Farcomeni A, Vestri AR, Lip GY, Basili S; ARAPACIS (Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study) STUDY Investigators. Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study. *Thromb Haemost*. 2016 Apr;115(4):856-63. doi: 10.1160/TH15-07-0612.
171. **Proietti M**, Raparelli V, Basili S, Olshansky B, Lip GY. Relation of female sex to left atrial diameter and cardiovascular death in atrial fibrillation: The AFFIRM Trial. *Int J Cardiol*. 2016 Mar 15;207:258-63. doi: 10.1016/j.ijcard.2016.01.169.
172. **Proietti M**, Lip GY. Edoxaban in venous thromboembolism and stroke prevention: an appraisal. *Vasc Health Risk Manag*. 2016 Feb 29;12:45-51. doi: 10.2147/VHRM.S81569.
173. **Proietti M**, Marra AM, Tassone EJ, De Vuono S, Corrao S, Gobbi P, Perticone F, Corazza GR, Basili S, Lip GY, Violi F, Raparelli V; ARAPACIS Study Investigators; GIS Group. Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation. *Am J Cardiol*. 2015 Sep 15;116(6):877-82. doi: 10.1016/j.amjcard.2015.05.060.
174. Xiong Q, Chen S, Senoo K, **Proietti M**, Hong K, Lip GY. The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients with atrial fibrillation: A systemic review and meta-analysis. *Int J Cardiol*. 2015 Sep 15;195:237-42. doi: 10.1016/j.ijcard.2015.05.115.
175. Basili S, **Proietti M**, Perticone F, Corazza GR, Violi F; ARAPACIS Study Investigators. Atrial fibrillation is not associated with increased risk of venous thromboembolism: Results from ARAPACIS study. *Thromb Haemost*. 2015 Aug 31;114(3):655. doi: 10.1160/TH15-02-0101.
176. Xiong Q, **Proietti M**, Senoo K, Lip GY. Asymptomatic versus symptomatic atrial fibrillation: A systematic review of age/gender differences and cardiovascular outcomes. *Int J Cardiol*. 2015 Jul 15;191:172-7. doi: 10.1016/j.ijcard.2015.05.011.
177. **Proietti M**, Lip GY. Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAME-TT2R2 score. *Eur Heart J Cardiovasc Pharmacother*. 2015 Jul;1(3):150-2. doi: 10.1093/ehjcvp/pvv012. Epub 2015 Mar 4.
178. Violi F, Pastori D, Perticone F, Hiatt WR, Sciacqua A, Basili S, **Proietti M**, Corazza GR, Lip GY, Pignatelli P; ARAPACIS (Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study) STUDY group. Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study. *BMJ Open*. 2015 May 21;5(5):e008026. doi: 10.1136/bmjopen-2015-008026.
179. **Proietti M**, Lip GY. Non-steroidal anti-inflammatory drugs and incident atrial fibrillation. *Eur Heart J Cardiovasc Pharmacother*. 2015 Apr;1(2):115-6. doi: 10.1093/ehjcvp/pvv007. Epub 2015 Mar 10. Erratum in: *Eur Heart J Cardiovasc Pharmacother*. 2015 Jul;1(3):211.
180. **Proietti M**, Calvieri C, Malatino L, Signorelli S, Corazza GR, Perticone F, Vestri AR, Loffredo L, Davì G, Violi F, Basili S; ARAPACIS (Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study) STUDY Investigators. Relationship between carotid

- intima-media thickness and non valvular atrial fibrillation type. *Atherosclerosis*. 2015 Feb;238(2):350-5. doi: 10.1016/j.atherosclerosis.2014.12.022.
181. **Proietti M**, Lip GY. Antidotes to non-vitamin K oral anticoagulants: necessary or not? *Expert Opin Pharmacother*. 2015;16(11):1573-6. doi: 10.1517/14656566.2015.1057119.
 182. Basili S, Raparelli V, **Proietti M**, Napoleone L, Ferroni P, Franconi F. Old And New Oral Anticoagulants In Management Of Atrial Fibrillation: A Double-Edged Sword For Women. *Curr Vasc Pharmacol*. 2015;13(6):738-48. doi: 10.2174/1570161113666150216152054.
 183. Basili S, Raparelli V, **Proietti M**, Tanzilli G, Franconi F. Impact of sex and gender on the efficacy of antiplatelet therapy: the female perspective. *J Atheroscler Thromb*. 2015;22(2):109-25. doi: 10.5551/jat.24935.
 184. Raparelli V, **Proietti M**, Buttà C, Di Giosia P, Sirico D, Gobbi P, Corrao S, Davì G, Vestri AR, Perticone F, Corazza GR, Violi F, Basili S. Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. *Intern Emerg Med*. 2014 Dec;9(8):861-70. doi: 10.1007/s11739-014-1096-1.
 185. Cangemi R, Casciaro M, Rossi E, Calvieri C, Bucci T, Calabrese CM, Taliani G, Falcone M, Palange P, Bertazzoni G, Farcomeni A, Grieco S, Pignatelli P, Violi F; **SIXTUS Study Group**. Platelet activation is associated with myocardial infarction in patients with pneumonia. *J Am Coll Cardiol*. 2014 Nov 4;64(18):1917-25. doi: 10.1016/j.jacc.2014.07.985.
 186. Raparelli V, **Proietti M**, Napoleone L, Bucci T, Talerico G, Pignataro FS, Basili S. Asymptomatic peripheral artery disease and antiplatelet management. *Vasa*. 2014 Sep;43(5):309-25. doi: 10.1024/0301-1526/a000369.
 187. Basili S, Raparelli V, Napoleone L, Del Ben M, Merli M, Riggio O, Nocella C, Carnevale R, Pignatelli P, Violi F; **CALC Group**. Polyunsaturated fatty acids balance affects platelet NOX2 activity in patients with liver cirrhosis. *Dig Liver Dis*. 2014 Jul;46(7):632-8. doi: 10.1016/j.dld.2014.02.021.
 188. Cangemi R, Celestini A, Del Ben M, Pignatelli P, Carnevale R, **Proietti M**, Calabrese CM, Basili S, Violi F. Role of platelets in NOX2 activation mediated by TNF α in heart failure. *Intern Emerg Med*. 2014 Mar;9(2):179-85. doi: 10.1007/s11739-012-0837-2. Epub 2012 Jul 28. PMID: 22843319.
 189. Violi F, Davì G, Hiatt W, Lip GY, Corazza GR, Perticone F, **Proietti M**, Pignatelli P, Vestri AR, Basili S; ARAPACIS Study Investigators. Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy. *J Am Coll Cardiol*. 2013 Dec 10;62(23):2255-6. doi: 10.1016/j.jacc.2013.07.035.
 190. Cangemi R, Pignatelli P, Carnevale R, Corazza GR, Pastori D, Farcomeni A, Basili S, Davì G, Ferro D, Hiatt WR, Licata G, Lip GY, Loffredo L, Mannucci PM, Vestri A, Violi F; **ARA PACIS study group**. Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. *Int J Cardiol*. 2013 Oct 9;168(4):3241-7. doi: 10.1016/j.ijcard.2013.04.142.
 191. Cangemi R, Pignatelli P, Carnevale R, Nigro C, **Proietti M**, Angelico F, Lauro D, Basili S, Violi F. Platelet isoprostane overproduction in diabetic patients treated with aspirin. *Diabetes*. 2012 Jun;61(6):1626-32. doi: 10.2337/db11-1243.
 192. Pignatelli P, Tanzilli G, Carnevale R, Di Santo S, Loffredo L, Celestini A, **Proietti M**, Tovaglia P, Mangieri E, Basili S, Violi F. Ascorbic acid infusion blunts CD40L upregulation in patients undergoing coronary stent. *Cardiovasc Ther*. 2011 Dec;29(6):385-94. doi: 10.1111/j.1755-5922.2010.00168.x.
 193. Basili S, Raparelli V, Riggio O, Merli M, Carnevale R, Angelico F, Tellan G, Pignatelli P, Violi F; **CALC Group**. NADPH oxidase-mediated platelet isoprostane over-production in cirrhotic patients: implication for platelet activation. *Liver Int*. 2011 Nov;31(10):1533-40. doi: 10.1111/j.1478-3231.2011.02617.x.
 194. Pignatelli P, Tellan G, Marandola M, Carnevale R, Loffredo L, Schillizzi M, **Proietti M**, Violi F, Chirletti P, Delogu G. Effect of L-carnitine on oxidative stress and platelet activation after major surgery. *Acta Anaesthesiol Scand*. 2011 Sep;55(8):1022-8. doi: 10.1111/j.1399-6576.2011.02487.x.
 195. Palmirotta R, Ferroni P, Ludovici G, Martini F, Savonarola A, D'Alessandro R, Raparelli V, **Proietti M**, Scarno A, Riondino S, Basili S, Guadagni F. VEGF-A gene promoter polymorphisms and microvascular complications in patients with essential hypertension. *Clin Biochem*. 2010 Sep;43(13-14):1090-5. doi: 10.1016/j.clinbiochem.2010.06.020.

ORGANIZZAZIONE, DIREZIONE E COORDINAMENTO DI CENTRI O GRUPPI DI RICERCA NAZIONALI E INTERNAZIONALI O PARTECIPAZIONE AGLI STESSI

(per ciascuna voce inserire anno, ruolo, gruppo di ricerca, ecc.)

- Research Fellow, Centro Aterotrombosi, Dipartimento di Medicina Interna e Specialità Mediche, Sapienza-Università di Roma, dal 2010 al 2015
- Research Fellow e Clinical Trials Physician, Institute of Cardiovascular Sciences, University of Birmingham, dal 02/2015 al 03/2017
- Research Fellow, Studio 'EURObservational Research Programme in Atrial Fibrillation' (EORP-AF) dell'EURObservational Research Programme della European Society of Cardiology (ESC) dal 2015
- Research Fellow, Dipartimento di Neuroscienze, Laboratorio di Valutazione della Qualità delle Cure e dei Servizi per l'Anziano, Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, dal 05/2017 al 06/2019
- Membro dello Steering Committee e del Comitato Valutazione degli Eventi dello studio 'Apixaban for the Reduction of Thrombo-Embolic in Patients with Device-Detected Sub-Clinical Atrial Fibrillation' (ARTESiA) dal 2018
- Research Fellow, Liverpool Centre for Cardiovascular Science, Institute of Life Course and Medical Sciences, University of Liverpool and Liverpool Heart & Chest Hospital, dal 06/2019
- Research Fellow, SC di Cardiologia, Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze, Università di Modena e Reggio Emilia, dal 06/2019
- Ricercatore a Tempo Determinato Tipo 'A' SSD MED/09, Università degli Studi di Milano presso UOSD Geriatria, IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico di Milano, dal 06/2019 al 01/2021 successivamente presso UO Medicina Interna ad Indirizzo Geriatrico, IRCCS Istituti Clinici Scientifici Maugeri di Milano dal 02/2021 al 06/2022
- Membro del Comitato Valutazione degli Eventi dello studio 'Secondary Prevention of Cardiovascular Disease in the Elderly' (SECURE) dal 2019
- Membro dello Steering Committee e Principal Investigator Italiano per lo studio 'Atrial fibrillation integrated approach in frail, multimorbid and polymedicated older people' (AFFIRMO) Programme dal 2021

ATTIVITÀ QUALI LA DIREZIONE O LA PARTECIPAZIONE A COMITATI EDITORIALI DI RIVISTE SCIENTIFICHE

(per ciascuna voce inserire anno, ruolo, rivista scientifica, ecc.)

- Editorial Board Member, European Journal of Internal Medicine, 2017-2018
- Section Editor, Thrombosis and Haemostasis, dal 2019
- Managing Editor, Archives of Medical Sciences, dal 2019
- Editorial Board Member, Journal of Frailty and Aging, dal 2020
- Associate Editor, Frontiers in Cardiovascular Medicine, dal 2022

PREMI E RICONOSCIMENTI NAZIONALI E INTERNAZIONALI PER ATTIVITÀ DI RICERCA

(inserire premio, data, ente organizzatore, ecc.)

- Fellow of the European Society of Cardiology (FESC), per riconosciute rilevanti attività scientifiche, della European Society of Cardiology (ESC) dal 2018
- Fellow of the European Heart Rhythm Association (FEHRA), per riconosciute rilevanti attività scientifiche, della European Heart Rhythm Association (FEHRA) dal 2019

PARTECIPAZIONE IN QUALITÀ DI RELATORE A CONGRESSI E CONVEGNI DI INTERESSE INTERNAZIONALE

(inserire titolo congresso/convegno, data, ecc.)

- 1 Relazione su Invito, Congresso annuale della Società Polacca di Cardiologia, 2017
- 1 Relazione su Invito, Congresso annuale della Società Polacca di Cardiologia, 2019
- 1 Relazione su Invito, Congresso annuale della Società Inglese di Aritmologia, 2019
- 1 Relazione su Invito, Medicine 2021, Congresso annuale del London Royal College of Physicians, 2021
- 1 Relazione su Invito, Heart & Stroke 2022, Congresso annuale del Council of Stoke della European Society of Cardiology (ESC), 14 Maggio 2022
- 2 Relazioni su Invito, Venice Arrhythmias 2022, 13-15 Ottobre 2022

ATTIVITÀ GESTIONALI, ORGANIZZATIVE E DI SERVIZIO

INCARICHI DI GESTIONE E AD IMPEGNI ASSUNTI IN ORGANI COLLEGIALI E COMMISSIONI, PRESSO RILEVANTI ENTI PUBBLICI E PRIVATI E ORGANIZZAZIONI SCIENTIFICHE E CULTURALI, OVVERO PRESSO L'ATENEO O ALTRI ATENEI

(inserire incarico/impegno, ente, data, ecc.)

- Coordinatore Nazionale del Gruppo "Giovani Internisti SIMI" della Società Italiana di Medicina Interna (SIMI) dall'Ottobre 2014 all'Ottobre 2016;
- Membro del Comitato Nazionale "AIAC Ricerca" dell'Associazione Italiana Aritmologia e Cardioritmo (AIAC) dal 2018;
- Membro del Comitato Nazionale Didattico-Formativo della Società Italiana di Medicina Interna (SIMI) dal 2021;
- Membro del Comitato Tecnico-Scientifico dell'IRCCS Istituti Clinici Scientifici Maugeri dal 2021;
- Membro del Board del Council on Stroke, in qualità di "Education and Scientific Programme Coordinator", della European Society of Cardiology (ESC) dal 2022.

ATTIVITÀ CLINICO ASSISTENZIALI

(indicare, data, durata, ruolo, ente presso il quale si è prestata attività assistenziale, ecc.)

- Specializzando, UO Medicina Interna C, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma dal 2010 al 2015
- Clinical Trials Physician, Birmingham City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, dal 02/2015 al 03/2017
- Dirigente Medico I Livello, UOSD Geriatria, IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico di Milano, dal 06/2019 al 01/2021
- Dirigente Medico I Livello, UO Medicina Interna ad Indirizzo Geriatrico, IRCCS Istituti Clinici Scientifici Maugeri di Milano, dal 02/2021 ad oggi

Data

04/09/2022

Luogo

Milano